Small Pharmaceuticals

Panacea Biotec Ltd.

PANACEABIO

₹478.8

-5.0% (-25.2)

Market Cap

₹2,934 Cr.

P/E

0.00

Panacea Biotec Ltd.

Price
Growth Table
Balance Sheet
Profit & Loss
Cash Flow
Cash Flow Analysis
Ratios
Quarterly Results
Reverse DCF

FAQs on Panacea Biotec Ltd. Shareprice

Has the share price of Panacea Biotec grown faster than its competition?

Panacea Biotec has given lower returns compared to its competitors.
Panacea Biotec has grown at ~17.33% over the last 8yrs while peers have grown at a median rate of 23.2%

Is Panacea Biotec stock expensive?

Panacea Biotec is not expensive.
Latest PE of Panacea Biotec is 0.0, while 3 year average PE is 7.91.
Also latest EV/EBITDA of Panacea Biotec is 0.0 while 3yr average is 22.0.

View FAQ's On Business

Growth Table

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

In %	1yr	2yr	3yr	4yr	5yr	6yr	7yr	8yr	9yr	10yr
Share Price CAGR	269	99.29	48.50	5.13	26.19	17.30	11.01	16.75	16.43	14.11
TTM EPS CAGR	—	—	—	—	—	—	—	—	—	—
Sales CAGR	-0.01	10.25	-5.44	-2.74	0.55	3.58	2.31	0.34	-1.61	-1.92
PAT Margin (Abs Growth)	6.86	-155	22.05	35.51	-8.48	12.52	9.86	2.93	14.64	21.79
PE CAGR	—	—	-100.00	—	—	-100.00	—	—	-100.00	—
CFO CAGR	-99.98	-96.96	—	-76.07	—	—	—	—	—	—

* Share price and PE growth are updated everyday. All other fields are as of latest financial year end. EPS adjusted for bonus and splits.

Balance Sheet

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Assets	2,025	1,774	1,592	1,356	1,559	1,177	1,735	1,443	1,412	1,290
Non Current Assets	1,475	1,089	1,038	868	877	667	768	854	904	745
Net Block	1,071	1,001	949	806	657	609	622	600	569	551
Capital Work in Progress	116	30.41	39.92	22.51	24.01	34.42	17.26	42.32	101	93.51
Intangible Assets Under Development	10.36	21.71	32.41	14.12	14.50	13.18	12.35	14.32	26.78	34.54
Long Term Investments	5.19	7.01	5.25	5.33	5.58	0.07	0.07	0.07	0.07	0.07
Current Assets	549	703	565	508	683	474	951	562	485	545
Inventory	305	316	334	81.43	148	174	213	202	178	214
Accounts Receivable	142	142	136	88.73	68.52	84.68	81.66	60.09	57.42	72.56
Short Term Investments	3.52	0.27	2.03	—	—	—	5.00	13.42	40.36	3.15
Cash & Bank Balances	22.93	14.13	23.24	23.48	89.75	136	583	226	139	107
Liabilities	2,025	1,774	1,592	1,356	1,559	1,177	1,735	1,443	1,412	1,290
Shareholders Funds	449	356	309	350	199	-229	877	844	842	835
Share Capital	22.43	6.13	6.13	6.13	6.13	6.13	6.13	6.13	6.13	6.13
Reserves	426	350	303	344	161	-235	871	837	836	829
Non Current Liabilities	1,100	719	591	70.08	741	960	85.10	271	265	92.14
Secured Loans	866	705	560	8.90	584	675	0.23	0.18	—	—
Unsecured Loans	1.00	9.49	10.26	37.22	29.58	60.03	33.87	19.98	20.99	22.21
Current Liabilities	475	689	696	938	622	447	774	330	309	367
Accounts Payable	188	249	277	270	199	247	235	177	154	226
Short Term Loans	192	191	165	69.39	3.57	—	—	—	—	—

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

Increase
Decrease
Total

No data available.

*Data is as of latest FY end

Profit & Loss

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Sales	653	544	593	457	544	625	661	460	559	559
Operating Expenses	541	497	508	590	519	548	674	558	579	585
Raw Material	194	158	198	135	190	199	311	218	212	214
Material Cost (%)	33.04	27.48	31.59	37.72	28.82	32.75	39.65	54.93	41.16	34.33
Employee Cost	142	148	152	147	144	156	183	126	150	173
Power & Fuel Cost	25.15	30.55	33.52	34.55	29.74	30.94	37.82	31.95	35.95	—
Operating Profit	112	47.12	84.53	-133	25.49	76.63	-13.20	-97.96	-20.06	-25.91
Other Income	20.35	46.59	8.23	5.06	30.35	9.98	10.97	51.66	25.80	20.66
OPM (%)	17.11	8.66	14.26	-29.15	4.68	12.26	-2.00	-21.30	-3.59	-4.63
Depreciation and Amortisation	73.32	67.95	58.53	55.03	44.13	45.59	43.78	39.12	36.71	34.81
Interest	127	101	101	105	174	185	181	4.44	3.58	3.88
Profit Before Tax	-18.93	-67.45	-66.35	46.08	-178	-144	1,449	12.81	1.48	-7.95
Tax	1.92	-10.98	9.86	8.56	16.95	1.96	371	46.55	2.98	0.77
Net Profit	-18.29	-54.48	-73.98	37.73	-194	-148	1,078	-33.24	-1.17	-8.72
Number of shares(Crs)	6.13	6.13	6.13	6.13	6.13	6.13	6.13	6.13	6.13	—
Dividend Payout Ratio(%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

TTM Values as of Mar 2025

Cash Flow

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

In Rs. Cr.	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Sep'24
Cash from Operating Activity	90.69	131	118	105	-30.47	107	-108	-422	-0.10	24.68
Profit Before Tax	-18.93	-67.18	-66.14	46.23	-177	-145	1,449	12.81	1.48	-16.06
Adjustments	149	150	167	-70.58	253	231	-1,455	-95.87	-8.76	-49.71
OCF Before Working Capital	130	82.39	100	-24.35	75.70	85.85	-5.61	-83.06	-7.28	-65.77
Working Capital Changes	-58.26	43.32	21.45	127	-97.50	21.91	301	-337	9.69	91.22
Taxes Paid	19.13	4.96	-3.91	1.83	-8.67	-0.99	-404	-2.48	-2.51	-0.77
Cash from Investing Activity	16.44	-25.83	55.29	-5.27	-34.76	-47.68	1,283	430	10.23	-11.14
Net Fixed Assets Purchased	-5.59	-23.68	-15.20	-4.78	9.19	-17.51	-10.51	-1.44	-71.03	-42.36
Fixed Assets Purchased	-11.32	-23.89	-15.22	-4.78	-6.91	-21.76	-12.51	-40.95	-77.72	-42.36
Fixed Assets Sold	5.73	0.21	0.01	—	16.11	4.26	2.00	39.51	6.68	—
Investment Purchased	-2.07	-0.18	-3.99	-3.77	-45.29	-150	-1,049	-868	-347	-211
Investment Sold	22.28	1.84	2.21	2.03	0.07	117	517	1,288	420	211
Interest Recieved	1.58	1.82	-0.15	1.09	5.26	3.43	3.28	11.56	8.37	7.85
Dividends Recieved	0.24	0.16	0.09	0.17	0.00	—	—	0.50	0.01	—
Subsidiary Investments	—	—	72.42	—	—	5.59	—	—	—	—
Cash from Financing Activity	-117	-107	-164	-101	90.74	-47.11	-1,176	-18.37	-2.81	-2.93
Proceeds From Shares	—	—	—	—	—	—	—	—	—	—
Net Long Term Borrowings	-43.69	-10.02	-29.02	-15.54	170	55.85	-786	-14.77	-0.24	0.00
Proceeds From Borrowings	—	—	5.80	—	743	101	0.30	—	—	—
Repayment From Borrowings	-43.69	-10.02	-34.81	-15.54	-573	-45.35	-786	-14.77	-0.24	—
Interest Paid	-75.90	-99.30	-109	-66.39	-45.02	-99.40	-390	-3.60	-2.57	-2.72
Dividend Paid	—	—	—	—	—	—	—	—	—	—
Net Cash Flow	-10.25	-2.13	8.97	-1.61	25.51	11.97	-1.72	-10.49	7.32	10.61
Opening Cash & Cash Equivalents	19.97	9.59	7.47	16.44	14.47	40.22	52.08	50.35	39.85	—
Effect of FX	0.01	—	—	—	—	—	-0.01	-0.00	0.00	—
Closing Cash & Cash Equivalents	9.73	7.47	16.44	14.47	40.22	52.08	50.35	39.85	47.17	—
Net Capex (est)	5.59	23.68	15.20	4.78	-9.19	17.51	10.51	1.44	71.03	42.36
Free Cash Flow (est)	85.10	107	103	100	-21.28	89.26	-119	-424	-71.13	-17.68

Cash Flow Analysis

Increase
Decrease
Total

No data available.

Ratios

= Dominant Factor

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Operational Ratios
Quick Ratio	0.31	0.51	0.56	0.33	0.45	0.86	0.67	0.95	1.09	0.99
Liquid Assets (Crs)	216	244	389	231	426	536	300	738	360	307
Current Liabilities (Crs)	706	475	689	696	938	622	447	774	330	309
Current Ratio	0.74	1.16	1.02	0.81	0.54	1.10	1.06	1.23	1.71	1.57
Current Assets (Crs)	526	549	703	565	508	683	474	951	562	485
Current Liabilities (Crs)	706	475	689	696	938	622	447	774	330	309
Interest Coverage Ratio	0.05	0.85	0.33	0.34	1.44	-0.02	0.22	9.01	3.89	1.41
EBIT (Crs)	5.12	58.74	25.76	34.23	-183	11.70	41.01	-46.01	-85.42	-30.98
Interest Expenses (Crs)	105	127	101	101	105	174	185	181	4.44	3.58
Fixed Asset Turnover	0.42	0.40	0.34	0.37	0.33	0.42	0.49	0.50	0.35	0.43
Net Sales (Crs)	687	653	544	593	457	544	625	661	460	559
Fixed Assets (Crs)	1,633	1,620	1,600	1,606	1,393	1,282	1,266	1,314	1,331	1,312
Cash Conversion Cycle	54.67	108	-237	97.52	42.34	-48.60	-265	-190	-83.17	-103
Inventory Days	141	172	203	199	166	76.86	89.66	102	160	122
Days Receivable	51.36	67.10	92.84	85.16	89.81	52.75	42.68	43.66	54.62	37.70
Days Payable	137	131	533	187	214	178	397	335	298	263
Debt to Equity Ratio	2.32	2.43	2.79	3.05	1.85	3.73	-3.58	0.04	0.02	0.02
Total Debt (Crs)	1,095	1,088	994	941	646	742	820	34.16	20.22	20.99
Shareholders Equity (Crs)	471	449	356	309	350	199	-229	877	844	842
Free Cash Flow/Sales (%)	4.31	13.03	19.67	17.35	21.90	-3.91	14.29	-17.99	-92.16	-12.72
Free Cash Flow(est) (Crs)	29.65	85.10	107	103	100	-21.28	89.26	-119	-424	-71.13
Net Sales (Crs)	687	653	544	593	457	544	625	661	460	559
Profitability Ratios
Gross Margin (%)	59.22	66.96	72.52	68.41	62.28	71.18	67.25	60.35	45.07	58.84
Op Profit Margin (%)	6.39	17.11	8.66	14.26	-29.15	4.68	12.26	-2.00	-21.30	-3.59
Operating Profit (Crs)	72.36	132	93.71	92.77	-128	55.84	86.61	-2.23	-46.30	5.74
Net Sales (Crs)	687	653	544	593	457	544	625	661	460	559
Net Profit Margin (%)	-15.50	-2.80	-10.02	-12.48	8.26	-35.71	-23.64	163	-7.23	-0.21
Net Profit (Crs)	-107	-18.29	-54.48	-73.98	37.73	-194	-148	1,078	-33.24	-1.17
Net Sales (Crs)	687	653	544	593	457	544	625	661	460	559
ROCE (%)	0.37	3.79	2.37	3.82	-43.86	1.25	5.62	-4.79	-7.68	-2.81
EBIT (Crs)	5.12	58.74	25.76	34.23	-183	11.70	41.01	-46.01	-85.42	-30.98
Capital Employed (Crs)	1,393	1,550	1,085	897	417	936	730	961	1,113	1,103
Return on Assets (%)	-5.07	-0.90	-3.07	-4.65	2.78	-12.46	-12.54	62.15	-2.30	-0.08
Net Profit (Crs)	-107	-18.29	-54.48	-73.98	37.73	-194	-148	1,078	-33.24	-1.17
Total Assets (Crs)	2,099	2,025	1,774	1,592	1,356	1,559	1,177	1,735	1,443	1,412
ROIC (%)	-2.35	3.41	-1.67	3.55	-40.82	-3.13	5.83	-13.39	55.35	8.16
Op Profit after Taxes (Crs)	-24.08	42.28	-17.44	29.86	-153	-20.43	31.46	-42.39	361	57.85
Invested Capital (Crs)	1,023	1,240	1,042	840	375	653	540	317	653	709
ROE (%)	-22.60	-4.08	-15.32	-23.97	10.77	-97.73	64.58	123	-3.94	-0.14
Net Profit Margin (%)	-15.50	-2.80	-10.02	-12.48	8.26	-35.71	-23.64	163	-7.23	-0.21
Asset Turnover ratio	0.33	0.32	0.31	0.37	0.34	0.35	0.53	0.38	0.32	0.40
Equity Multiplier	4.45	4.51	4.99	5.16	3.87	7.84	-5.15	1.98	1.71	1.68
Adjusted EPS	-17.38	-2.98	-8.90	-12.08	6.16	-31.72	-24.11	176	-5.43	-0.19
Valuation Ratios
P/E	0.00	0.00	0.00	0.00	32.18	0.00	0.00	0.84	0.00	0.00
Price to Book	-188	-20.94	2.77	5.30	3.46	4.02	-4.75	1.04	0.79	0.88
EV/EBITDA	26.50	12.50	20.95	27.53	-14.34	23.70	20.44	-161	-9.89	109
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Quarterly Results

Panacea Biotec Ltd.
Zota Health Care
Loading...
Orchid Pharma
Loading...

In Rs. Cr.	Dec'22	Mar'23	Jun'23	Sep'23	Dec'23	Mar'24	Jun'24	Sep'24	Dec'24	Mar'25
Net Sales	115	129	129	143	151	136	116	147	163	133
Operating Expenses	124	135	140	147	151	143	130	140	156	159
Increase/Decrease in Stock	-2.25	-2.03	-3.66	-1.59	18.40	4.71	1.48	1.42	13.66	-38.69
Raw Material	48.07	59.51	57.32	59.78	47.83	45.53	40.24	41.77	48.74	83.32
Employee Cost	32.02	30.55	35.97	37.52	37.65	38.43	37.50	43.44	42.98	49.13
Selling and Distribution Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Electricity, Power & Fuel Cost	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gen_AdminExpenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Miscellaneous Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Profit	-8.64	-5.67	-10.31	-3.56	-0.15	-6.04	-13.99	7.00	7.96	-26.88
Other Income	13.94	15.06	6.08	3.23	5.68	10.81	3.80	4.65	3.62	8.59
Interest	0.96	1.05	1.00	0.91	0.85	0.82	0.87	0.98	0.99	1.04
PBDT	32.11	27.72	22.51	1.53	7.46	6.69	-8.32	13.44	13.36	8.38
Depreciation and Amortization	9.67	9.51	9.48	9.31	9.11	8.81	8.73	8.68	8.98	8.42
Profit Before Tax	22.44	18.21	13.03	-7.78	-1.65	-2.12	-17.05	4.76	4.38	-0.04
Tax	3.07	30.89	2.05	0.51	0.55	-0.13	-1.17	0.05	-0.06	1.95
Profit After Tax	19.37	-12.68	10.98	-8.29	-2.20	-1.99	-15.88	4.71	4.44	-1.99
Exceptional Items	27.77	19.38	27.74	2.77	2.78	2.74	2.74	2.77	2.77	27.71
Net Profit	19.37	-12.41	10.91	-8.37	-2.28	-1.43	-15.80	4.80	4.52	-1.89
Quarterly Ratios
EPS	3.16	-2.02	1.78	-1.37	-0.37	-0.23	-2.58	0.78	0.74	-0.31
Operating Profit Margin	-7.50	-4.40	-7.98	-2.49	-0.10	-4.43	-12.09	4.75	4.87	-20.28
Net Profit Margin	16.81	-9.83	8.50	-5.80	-1.46	-1.46	-13.72	3.20	2.72	-1.50

Reverse DCF

Earnings

Discount Rate (%)

Terminal Multiple

5 YEAR

10 YEAR

20 YEAR

#N/A.0

Implied Growth Rate over a 5 year period*

#N/A.0

Implied Growth Rate over a 10 year period*

#N/A.0

Implied Growth Rate over a 20 year period*

*Implied Growth calculated using Newton-Rhapson method.

Learn how to use Reverse DCF

FAQs on Panacea Biotec Ltd. Financials

How strong is Panacea Biotec balance sheet?

Balance sheet of Panacea Biotec is strong.
But short term working capital might become an issue for this company.

Is the debt of Panacea Biotec increasing or decreasing?

Yes, The net debt of Panacea Biotec is increasing.
Latest net debt of Panacea Biotec is -₹84.76 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹257.94 Crs.

Is the profitablity of Panacea Biotec improving?

The profit is oscillating.
The profit of Panacea Biotec is -₹8.72 Crs for TTM, -₹1.17 Crs for Mar 2024 and -₹33.24 Crs for Mar 2023.

Does Panacea Biotec pay decent dividends?

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Panacea Biotec latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Panacea Biotec allocated its funds?

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Panacea Biotec Ltd.

Panacea Biotec Ltd.

Has the share price of Panacea Biotec grown faster than its competition?

Is Panacea Biotec stock expensive?

How strong is Panacea Biotec balance sheet?

Is the debt of Panacea Biotec increasing or decreasing?

Is the profitablity of Panacea Biotec improving?

Does Panacea Biotec pay decent dividends?

How has Panacea Biotec allocated its funds?

SIGN UP FOR FREE